News

U.S. authorities have granted a permanent billing code for Blenrep (belantamab mafodotin), an approved treatment for certain adults with hard-to-treat multiple myeloma., a…

A $16 million research initiative is bringing together scientists from six U.S. cancer centers to build on recent breakthroughs in targeted therapies and develop longer-lasting…

A regulatory committee in the European Union has recommended expanding approval of a dual regimen for hard-to-treat myeloma —…

A European Medicines Agency (EMA) committee is recommending expanded approval for Jaypirca (pirtobrutinib), an oral therapy used to treat chronic lymphocytic leukemia (CLL), a type…

Dosing has begun in a global clinical trial testing Revolution Medicines‘ RAS(ON) inhibitor candidate zoldonrasib as a first-line treatment for advanced pancreatic ductal carcinoma…

Starting the electrical therapy Optune Gio during radiation therapy and chemotherapy, rather than after it as indicated, did not extend survival in people with newly…

Weekly treatment with Context Therapeutics’ CTIM-76 was generally well tolerated and shrank tumors in some people with heavily pretreated platinum-resistant ovarian cancer, according…

Adults in the U.S. now have a new generic drug option — Bortezomib for Injection, an equivalent of the approved medication Velcade (bortezomib) —…

Nearly two-thirds of adults ages 80 and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), two related types of…

NeuExcell Therapeutics‘ investigational gene therapy, NXL-004, showed a potential survival benefit in a small group of people with recurrent malignant glioma in an…